CR Pharma’s Subsidiary CR Double-Crane Issues RMB1.00 Billion Three-Year Bonds at 1.65% Coupon

Bulletin Express

03/26

China Resources Pharmaceutical Group Limited (CR Pharma) announced that its 59.95%-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane), has completed the public issuance of the first tranche of 2026 corporate bonds to qualified investors in mainland China.

The offering raised up to RMB1.00 billion with a three-year maturity and carries an annual coupon rate of 1.65%. Net proceeds will be applied to repay interest-bearing debt and to supplement working capital, in line with the filing approved by the China Securities Regulatory Commission.

The transaction complies with Rule 13.09 of the Hong Kong Listing Rules and the Inside Information Provisions of the Securities and Futures Ordinance. CR Pharma advises shareholders and potential investors to exercise caution when dealing in its securities.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1129458795"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1129458795\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1129458795?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 19:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129458795","market":"hk","top_or_hot":-1,"title":"CR Pharma’s Subsidiary CR Double-Crane Issues RMB1.00 Billion Three-Year Bonds at 1.65% Coupon","media":"Bulletin Express","content":"<p>China Resources Pharmaceutical Group Limited (CR Pharma) announced that its 59.95%-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane), has completed the public issuance of the first tranche of 2026 corporate bonds to qualified investors in mainland China.</p>\n<p>The offering raised up to RMB1.00 billion with a three-year maturity and carries an annual coupon rate of 1.65%. Net proceeds will be applied to repay interest-bearing debt and to supplement working capital, in line with the filing approved by the China Securities Regulatory Commission.</p>\n<p>The transaction complies with Rule 13.09 of the Hong Kong Listing Rules and the Inside Information Provisions of the Securities and Futures Ordinance. CR Pharma advises shareholders and potential investors to exercise caution when dealing in its securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CR Pharma’s Subsidiary CR Double-Crane Issues RMB1.00 Billion Three-Year Bonds at 1.65% Coupon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCR Pharma’s Subsidiary CR Double-Crane Issues RMB1.00 Billion Three-Year Bonds at 1.65% Coupon\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-03-26 19:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>China Resources Pharmaceutical Group Limited (CR Pharma) announced that its 59.95%-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane), has completed the public issuance of the first tranche of 2026 corporate bonds to qualified investors in mainland China.</p>\n<p>The offering raised up to RMB1.00 billion with a three-year maturity and carries an annual coupon rate of 1.65%. Net proceeds will be applied to repay interest-bearing debt and to supplement working capital, in line with the filing approved by the China Securities Regulatory Commission.</p>\n<p>The transaction complies with Rule 13.09 of the Hong Kong Listing Rules and the Inside Information Provisions of the Securities and Futures Ordinance. CR Pharma advises shareholders and potential investors to exercise caution when dealing in its securities.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"華潤醫藥","start_time":0,"source_url":"","article_id":"1129458795","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129458795","pubTimestamp":1774523095,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China Resources Pharmaceutical Group Limited (CR Pharma) announced that its 59.95%-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane), has completed the public...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03320":"华润医药"},"translate_title":"华润医药子公司华润双鹤发行人民币10亿元三年期债券，票面利率为1.65%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"China Resources Pharmaceutical Group Limited (CR Pharma) announced that its 59.95%-owned subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane), has completed the public issuance of the first tranche of 2026 corporate bonds to qualified investors in mainland China.\nThe offering raised up to RMB1.00 billion with a three-year maturity and carries an annual coupon rate of 1.65%. Net proceeds will be applied to repay interest-bearing debt and to supplement working capital, in line with the filing approved by the China Securities Regulatory Commission.\nThe transaction complies with Rule 13.09 of the Hong Kong Listing Rules and the Inside Information Provisions of the Securities and Futures Ordinance. CR Pharma advises shareholders and potential investors to exercise caution when dealing in its securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}